论文部分内容阅读
目的 :采用Meta分析的方法评价芪参益气滴丸治疗肺源性心脏病的临床疗效。方法 :计算机检索数据库,搜集在西药常规治疗的基础上加用芪参益气滴丸治疗肺源性心脏病的RCT,检索时限均从建库至2016年9月30日。由2位评价员按照纳入与排除标准独立筛选文献、提取资料和评价纳入研究的方法后,采用Rev Man 5.3软件进行Meta分析。共纳入6个RCTs,共490例慢性肺源性心脏病患者。结果 :经分析显示,芪参益气滴丸+常规治疗组(治疗组)与常规治疗组(对照组)相比:可提高临床治疗有效率;改善心功能。结论 :在常规西药治疗的基础上加用芪参益气滴丸可有效改善慢性肺源性心脏病患者的心功能,提高临床总有效率,且不良反应少,耐受性好。虽然本研究所纳入文献数量较少,研究样本量有限,更需大量研究证据支持,但目前的结果已经可以显示芪参益气滴丸在肺源性心脏病方面的疗效与裨益,值得进一步深入研究与临床推广。
OBJECTIVE: To evaluate the clinical effect of Qishen Yiqi Drop Pills in the treatment of pulmonary heart disease by Meta-analysis. Methods: The database was searched by computer. We collected RCTs for treating pulmonary heart disease on the basis of routine treatment of western medicine. The search time was from building database to September 30, 2016. After two reviewers independently screened the literature for inclusion and exclusion criteria, extracted data and evaluated the included studies, the Meta-analysis was performed using RevMan 5.3 software. A total of 6 RCTs were enrolled, a total of 490 patients with chronic cor pulmonale. Results: The analysis showed that Qishen Yiqi drop pills + conventional treatment group (treatment group) compared with the conventional treatment group (control group): can improve the efficiency of clinical treatment; improve cardiac function. Conclusion: The Qishen Yiqi drop pills can effectively improve the cardiac function in patients with chronic cor pulmonale and improve the total effective rate of the clinical, with less adverse reactions and good tolerability. Although there are few articles in this study and the sample size is limited, there is a great deal of research evidence to support. However, the current results have shown the efficacy and benefit of Qishen Yiqi pills in patients with pulmonary heart disease, which deserves further study Research and clinical promotion.